Cell based flavor and fragrance company, Amyris, Inc. AMRS (NASDAQ) announced a cannabinoid development, licensing and commercialization partnership valued at up to $255 million with a confidential partner. According to the company’s press release, the $255 million will include an upfront payment and future payments based on milestones over the next 12-36 months. http://cellbased.link/26f0d
There are currently three other public companies working on cell based cannabinoid production.
– Cronos Group (CRON) in partnership with Ginkgo Bioworks
– Organigram (ORGIF) in partnership with Hyasynth Bio
– Intrexon (XON) in partnership with Next Green Wave (NXGWF)
What this means. Using cellular technology to propagate cannabis plant compounds in a lab has the potential to maximize yield and eliminates the traditional resources of land, water, light and seeds.